Abstract: Anticancer drug resistance demands innovative approaches that boost the activity of drugs against drugresistant cancers without increasing the systemic toxicity.Here we show the use of enzyme-instructed self-assembly (EISA) to generate intracellular supramolecular assemblies that drastically boost the activity of cisplatin against drug-resistant ovarian cancer cells.W ed esign and synthesize small peptide precursors as the substrates of carboxylesterase (CES). CES cleaves the ester bond pre-installed on the precursors to form the peptides that self-assemble in water to form nanofibers.At the optimal concentrations,t he precursors themselves are innocuous to cells,b ut they double or triple the activity of cisplatin against the drug-resistant ovarian cancer cells.T his work illustrates as imple,y et fundamental, new way to introduce non-cytotoxic components into combination therapies with cisplatin without increasing the systemic burden or side effects.
Sinceitsserendipitousdiscoveryfivedecadesago, [1] cisplatin has become the most successful therapeutic agent for anticancer chemotherapy.
[2] Particularly,c isplatin has drastically extended the progression-free survival (PFS) of patients with ovarian cancers. [3] However,o wing to the lack of early detection of ovarian cancer and the almost inevitable relapse in the patients with advanced ovarian cancer, drug resistance remains amajor obstacle in treating ovarian cancers. [4] Many approaches have been investigated to address the urgent need of treating drug-resistant ovarian cancers.O ne of the most explored strategies is combination chemotherapy (such as the combination of cisplatin with other therapeutics) because the advantages of cisplatin promote the rapid translation from preclinical to clinical settings.Despite the remarkable clinical success of combination therapies, [3] the 5-year relative survival rate of ovarian cancer hardly improved over the past decade (45 %( 2004-2010) vs.4 5% (1996-2003) ).
[4e] Thus, there is an urgent need for innovative approaches in cisplatinbased combination therapies.
We have been exploring enzyme-instructed molecular self-assembly [5] inside cells, [6] and we recently showed that intracellular molecular nanofibers promiscuously interact with cytoskeleton proteins [7] yet selectively inhibit cancer cells. [8] Recently,M aruyama and co-workers, [9] Pires and Ulijn, [10] Yang et al., [11] and Wells [12a] also reported inhibition of cancer cells by nanofibers formed by the self-assembly of small molecules.T he exceptional selectivity [8] and new mechanisms [7, 13] of the molecular nanofibers against cancer cells encouraged us to explore the utilization of enzymeinstructed intracellular molecular self-assembly for combination therapy with cisplatin. Unlike the previous approaches, this work focuses on the use of d-peptides for intracellular self-assembly,a nd is the first demonstration of combining intracellular enzyme-instructed self-assembly with cisplatin. We design and synthesize two enantiomeric peptidic precursors (l-1 and d-1)that turn into the self-assembling molecules (l-2 and d-2)u pon the catalysis of carboxylesterases (CES; Scheme 1).
[14] Our study confirms that CES are able to convert both l-1 and d-1 into the corresponding molecules of l-2 and d-2,respectively. l-2 or d-2 self-assembles in water to form molecular nanofibers.A tt he optimal concentration, l-1 or d-1 is innocuous to cells.T he co-incubation of l-1 or d-1 at the optimal concentration with cisplatin significantly boosts the activity of cisplatin against SKOV3a nd A2780cis, two lines of drug resistant ovarian cancer cells.The efficacy of this simple approach (inhibiting over 80 %o fS KOV3 by 20 mm of cisplatin and 15 mgmL À1 of d-1), in fact, is comparable to that of the innovative approach based on the co-delivery of siRNAa nd cisplatin nanoparticles (80 % inhibition of SKOV3b y7 5mm of cisplatin). [15] We chose to work on the enantiomeric precursors l-1 and d-1 to assess the influences of the cell uptake of the precursors and the proteolytic stability of the intracellular nanofibers to the efficacyo fc ombination therapy.T hese results confirm that enzyme-instructed self-assembly promises anew approach to boost the activity of cisplatin against drug-resistant ovarian cancers without increasing the systemic toxicity.
Thesynthesis of 1 and 2 is simple and straightforward. The facile synthetic route (Supporting Information, Scheme S1) combines liquid-phase synthesis and solid-phase peptide synthesis (SPPS) for making the precursors.F or example,b y loading N-Fmoc-protected phenylalanine (Fmoc-Phe-OH) onto 2-chlorotrityl resin and carrying out SPPS,w eo btain Nap-FF [16] for coupling with ethanolamine to produce l-2. After l-2 reacts with succinic anhydride,a nother step of amide bond formation allows the attachment of taurine to form l-1.After the purification by HPLC,the overall yield of l-1 is about 60 %. Thesame synthetic approach also produces d-1.
Because enzyme-instructed self-assembly usually leads to the formation of supramolecular hydrogels, [17] we evaluated the hydrogelation resulting from the esterase catalyzed conversion of l-1 and d-1 as af acile method to assay the self-assembly.A fter obtaining the precursors,w etested the use of CES to convert the precursors into the hydrogelators that self-assembly in water to form molecular nanofibers.The addition of l-1 (or d-1)i nP BS buffer at pH 7.4 at ac oncentration of 0.4 wt %( 5.5 mm)a fforded at ransparent solution. After the addition of CES (2 UmL À1 )i nto the solution of l-1 (or d-1), atranslucent hydrogel formed after 24 h. We also found the minimum gelation concentration (mgc) of l-2 or d-2 is about 0.1 wt %( 1.4 mm). While CES efficiently converts both l-1 and d-1 into l-2 and d-2,r espectively,t he hydrogel of l-2 is apparently weaker than the hydrogel of d-2 (Supporting Information, Figure S5 ). We speculate that this subtle difference might originate from weaker interactions between d-2 and CES than between l-2 and CES.T he transmission electron microscopy (TEM) images of the resulting hydrogels reveal the formation of uniform nanofibers after the addition of CES ( Figure 1A ,B). Thed iameters of the nanofibers of the hydrogel formed by l-2 or d-2 after the addition of CES in the solution of l-1 or d-1 are 10 AE 2nmor8AE 2nm, respectively.
Our preliminary test of the cytotoxicity of l-1 and d-1 indicates that l-1 and d-1 show significant cytotoxicity to SKOV3c ells at concentrations below the mgc (Supporting Information, Figure S4 ). Thus,w eu sed static light scattering (SLS) to help verify the existence of nanoscale assemblies (for example,n anofibers or nanoparticles) in the solution of l-1 (or d-1)atconcentrations lower than the mgc and after the addition of CES (2 UmL À1 ). We chose the concentrations from 10 mm to 100 mm to analyze whether there are differences in self-assembly of the molecules before and after the addition of CES.B efore being treated with CES,t he signal intensity ratios of the solution of l-1 (or d-1)a tc oncentrations from 10 mm to 50 mm were close to zero ( Figure 1C,D) , indicating that there are hardly any assemblies of l-1 (or d-1)i nt he solution. When the concentration of the solution of l-1 (or d-1)increases to 100 mm,there was aslight increase of intensity ratio,suggesting that small amounts assemblies of l-1 (or d-1) exist in the solution. In contrast, the addition of CES to the solution of l-1 (or d-1)a tc oncentrations from 10 mm to 100 mm results in as ignificant increase of the signal intensity ratios,especially when the concentration of l-1 (or d-1)i sa t or above 50 mm.F or example,the signal intensity ratio of the solution of l-1 (or d-1)a t5 0mm drastically increased from about zero (before the addition of CES) to about 17 (after the addition of CES), which revealed the formation of assemblies of l-2 (or d-2). Moreover,the solution of 100 mml-1 showed a9-fold increase of the signal intensity ratio after the addition of CES,i ndicating the formation of al arger amount of assemblies after enzymatically converting the precursors to the hydrogelators (Supporting Information, Figure S6 ). Similarly,t he signal intensity ratio of the solution of 100 mmd -1 increased significantly after the addition of CES,w hich agrees with the observation that CES converts d-1 into d-2 to form self-assembling nanoscale assemblies of d-2 in water ( Figure 1B) .
After confirming that CES converts the precursor l-1 (or d-1)i nto the hydrogelator l-2 (or d-2), we determined the stability of the precursors (l-1 or d-1)w hen incubated with the ovarian cancer cells.A fter culturing the precursors with SKOV3orA2780cis cells at 37 8 8Cfor 4h,wecollected the cell . .
lysates and culture medium for liquid chromatography-mass spectrometry (LC-MS) analysis and determined the intracellular concentrations of the precursors,t he hydrogelators, and the relevant proteolyzed products.After incubation with SKOV3o rA 2780cis cells for 4h,m ore than 85 %o ft he precursors (l-1 or d-1)t urned into the corresponding hydrogelators (l-2 or d-2;T able 1). Moreover,t he intracellular concentrations of the hydrogelators were all above 100 mm, which indicates the intracellular self-assembly of the hydrogelators.T he cumulative intracellular concentration of l-1 and l-2 was also about 10-fold higher than the incubation concentration of l-1,a nd the cumulative intracellular concentration of d-1 and d-2 was about 5-fold higher than the incubation concentration of d-1.T hese results not only indicate that the cellular uptake of l-1 is more efficient than that of d-1,b ut also confirm that the selective retention of hydrogelators inside the cells originates from ester bond cleavage catalyzed by CES.Afluorescent esterase substrate, 6-CFDA, [18] also confirmed high esterase activity in SKOV3 cells (Supporting Information, Figure S7 ). We also analyzed the culture medium containing l-1 (or d-1), which was incubated with SKOV3c ells or A2780cis cells.A fter 4h incubation with SKOV3c ells,a bout 19 %o fl-1 in the medium turned into l-2 (Supporting Information, Table S2 ), and the concentration of l-1 in the medium decreased from 50 mm to 39 mm ;a bout 15 %o fd-1 converted d-2,a nd the concentration of d-1 in the medium decreased from 20 mm to 16 mm.Asimilar trend was also observed in A2780cis cells. These results further validate the hypothesis that intracellular enzymatic conversion of the precursors catalyzed by CES results in the intracellular self-assembly of the hydrogelators.
To evaluate the effect of intracellular self-assembly of l-2 or d-2 for cisplatin-based combination therapy,w et est the cell viability of three ovarian cancer cell lines by incubating them with the mixture of precursors and cisplatin (CDDP). After 72 h, the mixture of CDDP (6 mgmL À1 )w ith d-1 (15 mgmL À1 )o rl-1 (37 mgmL À1 )i nhibits about 74 %o r 87 %, respectively,o fS KOV3 cells (Figure 2A ). In contrast, d-1 (15 mgmL À1 )o rl-1 (37 mgmL À1 )a lone is almost innocuous to the cells,a nd CDDP (6 mgmL À1 )a lone inhibits only 48 %SKOV3 cells.W ealso used another method to treat the SKOV3cells,inwhich the d-1 (or l-1)were added 12 hafter the addition of CDDP to SKOV3c ells.A ss hown in Fig Table S2 ), but their concentrations for the combination therapy can be lower than IC 50 values because EISA accumulates the hydrogelators intracellularly.Furthermore,the intracellularly formed nanofibers (of d-1)a re about seven times more effective against HeLa cells than the nanofibers of the dipeptides reported previously (Nap-FF [8] ;Supporting Information, Table S3 ). To verify the critical role of enzyme-instructed selfassembly,w es ynthesize ac ontrol compound (3), which replaces the ester bond in d-1 by an amide bond (Supporting Information, Scheme S2). This change ( À COO À to À CONH À )r enders 3 resistant to CES.C ontrol compound 3 (500 mm) alone hardly inhibited SKOV3c ells after 72 hi ncubation ( Supporting Information, Figures S8 A, S9 A) . After 72 h incubation with SKOV3c ells,w hile CDDP (6 mgmL À1 ) alone causes about 40 %c ell death, the mixture of 3 (15 mgmL À1 )a nd CDDP (6 mgmL À1 )i nhibited only about 32 %ofSKOV3 cells.The innocuous effects of 3 also exclude the possibility that l-1 or d-1 act as asurfactant to inhibit cell survival. As imilar trend is observed in A2780cis cells ( Supporting Information, Figures S8 B, S9 B) . These results further confirm that enzyme-instructed self-assembly inside 
Angewandte
Chemie cells is the main cause for boosting the efficacyo fC DDP in the combination therapy of CDDP with the precursors (d-1 and l-1). Some of the cell viabilities slightly exceed 100 % (for example,F igure 2B)b ecause MTT assay measures the activity of mitochondrial reductase and it is not unusual for treated groups to have higher enzyme activity than the control group.
To gain insight into the action of intracellular selfassembly within cells,w ee xamined the change of the actin filaments inside cells.S KOV3 cells treated by d-1 (20 mm (15 mgmL À1 ), 20 h) exhibit far fewer well-defined, long actin filaments than that in the control SKOV3c ells (without the treatment of d-1;F igure 3). This trend becomes more pronounced after increasing the concentration from 20 to 100 mm (Supporting Information, Figure S11 ), as evidenced by the number of the actin filaments in the cells (Supporting Information, Figure S19 ). This observation agrees with hypothesis that the intracellular nanofibers of small peptides interact with actin. [7] To verify the reversible assembly of d-2 inside cells,w et reated the SKOV3c ells with d-1 at the concentrations of 20, 50, and 100 mm respectively,f or 20 h, then replaced the media with fresh media and incubated the cells for an additional 20 h. Actin filaments recovered after being treated with fresh medium for 20 hw hen the concentrations of d-1 were 20 and 50 mm (Supporting Information, Figure S12 ). Theincomplete recovery of actin filaments,when [d-1] = 100 mm,supports the hypothesis that d-1 starts to selfassemble at 100 mm.A fter being incubated with l-1,S KOV3 cells exhibited similar behavior (Supporting Information, Figures S13, S14): after 20 h, cells incubated with l-1 (50 mm) exhibited fewer well-defined actin filaments compared with the cells without the treatment of l-1.H owever,2 0h after exchanging the media, the morphology of actin filaments was restored to normal. These results suggest that intracellular nanofibers formed by enzyme-instructed self-assembly exhibit transient cytotoxicity that should help minimize long-term systemic burden in combination therapy.D issociation likely reduces the long-term cytotoxicity after the apoptosis of cells so that the precursors and nanofibers cause minimal systemic toxicity.
In conclusion, we demonstrated that enzyme-instructed intracellular self-assembly of small molecules is an ew approach to boost the activity of CDDP against two drugresistant ovarian cancer cell lines.M oreover,a tt he optimal concentrations,20mm (d-1)and 50 mm (l-1)used for boosting the activities of the cisplatin, l-1 and d-1 hardly inhibit HS-5 and PC-12 cells ( Supporting Information, Figures S15, S17) , despite cisplatin significantly inhibiting HS-5 and PC-12 cells (Supporting Information, Figure S16) . [19] Intravenous injection of l-1 or d-1 hardly affected the weight and organ index of mice (Supporting Information, Figure S18 ), confirming the low systemic toxicity of the precursors.T he genome analysis according to TheC ancer Genome Atlas (TCGA) indicates the amplification of CES in certain tumors (for example, breast and ovarian cancer;S upporting Information, Figure S23) , which not only supports the observations in this work, but also provides useful guidance for treating other cancers based on the self-assembly of intracellular nanofibers. This work, together with other emerging evidence, [6] [7] [8] [9] [10] 12] indicates that enzyme-instructed self-assembly promises an ew way for developing combination therapy for cancer treatment. Other than cisplatin, carboplatin has been used as the preferred platinum-based drug, [20] and we will use carboplatin for our future work. . .
